Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT03951662 Withdrawn - HIV/AIDS Clinical Trials

Immunology of HIV and Alcoholic Hepatitis

Start date: July 1, 2020
Phase:
Study type: Observational

This is prospective, longitudinal cohort study involving HIV-positive, antiretroviral (ART)-treated, heavy alcohol drinking participants who have and do not have alcoholic hepatitis.

NCT ID: NCT03949764 Active, not recruiting - Hepatitis C Clinical Trials

The Kentucky Viral Hepatitis Treatment Study

KeY Treat
Start date: September 23, 2019
Phase: Phase 4
Study type: Interventional

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.

NCT ID: NCT03941821 Not yet recruiting - Chronic Hepatitis c Clinical Trials

Glecaprevir/Pibrentasvir Real-world Study in China

Start date: June 30, 2019
Phase:
Study type: Observational

To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study

NCT ID: NCT03939013 Completed - Hepatitis C Clinical Trials

Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)

CT2
Start date: January 30, 2019
Phase: N/A
Study type: Interventional

Implementation-effectiveness hybrid trial assessing acceptability, feasibility and cost-effectiveness of community-based point-of-care testing and treatment for hepatitis C. Utilises Cepheid GeneXpert HCV VL device as diagnostic tool (diagnosis of chronic infection and assessment of treatment outcome) and sofosbuvir/daclatasvir for HCV therapy (local standard of care).

NCT ID: NCT03933384 Recruiting - Hepatitis B Clinical Trials

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Start date: August 19, 2019
Phase: Phase 4
Study type: Interventional

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

NCT ID: NCT03932513 Terminated - Hepatitis B Clinical Trials

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

NCT ID: NCT03932396 Not yet recruiting - Mental Disease Clinical Trials

A Novel Hepatitis c micrOelimination Program in Non imprisonEd SenTenced With Alternative Measures

HONEST
Start date: May 10, 2019
Phase:
Study type: Observational

The objective of this study is to carry out a Micro-elimination program for HCV infection in a vulnerable population (people sentenced to non-custodial sentences). This group shares certain peculiarities with the prison population (vulnerability, addictions, mental disorders, etc.), is three times higher than the imprisoned population, and is regularly attended by Social Insertion Centers (CIS) in Spain. An additional objective is to link these people with the specific plans of the Government of Cantabria (Chronicity Plan, Care for Serious Mental Disorders, Harm Reduction Programs and the Center for Attention to Drug Addicts) as well as the Extended Bridge Program for Penitentiary Institutions, implementing the figure of a Navigator (a specialized professional in charge of helping subjects overcome barriers). It is an observational study based on the screening of disease in accordance with the recommendations of the health authorities. Once detected, patients will be referred to the corresponding specialized care following the usual clinical practice.

NCT ID: NCT03931239 Completed - Hepatitis B Clinical Trials

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate safety and tolerability of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed in Vietnamese infants aged 6-12 weeks. This is an open label, single group, bridging study.

NCT ID: NCT03920618 Recruiting - Hepatitis B Clinical Trials

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

NCT ID: NCT03920605 Recruiting - Hepatitis B Clinical Trials

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment experienced patients with HBV related liver fibrosis.